Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Ross Muken from Deutsche Bank. Please proceed.
Ross Muken - Deutsche Bank
Good afternoon, gentlemen. It’s a long day. So, as we look at the quarter I think obviously the growth is pretty astounding that you are able to keep this sort of trajectory, but I guess what's even more astounding sort of the degree to which you continue to innovate, we obviously have several new products that will start hitting the P&L in upcoming quarters.
In each year your key divisions you highlighted that on the call Jay, so where are we sort of in the innovation cycle in these markets and do you still think we are early in both genotyping and sequencing in terms of the -- what you can deliver to the end customer and is that demand still insatiable in terms of driving down cost per data point and them wanting to do more and more projects as it becomes sort of a boarder tool?
Jay Flatley
I guess, there is probably two components to the answer, Ross. One is thinking about this from a technology perspective, and I guess looking at it that way, I’d say that our feeling is our technology is both sequencing and in array business continued to have enormous headroom to get better in terms of density, in terms of the overall throughput, continuing to reduce costs, we are long way from ceiling like, where technology limit or bounded.
The other way to think about is from the market perspective, and sequencing it'svery clear that the demand for sequencing is going to be insatiable as far as we can see, and certainly it'sgoing to be a highly elastic market, so as the prices continue to go down, the kind of organisms, we are going to sequence and the amount of resequencing that's done is going to continue to increase enormously.
In the array business I suspect over the next two to five years, you'll begin to see some transitions there. We definitely expect whole-genome association study to continue for at least two to four more years there, robustly. We think we are going to see follow-on, more focused studies, continue and get ever more rich in terms of converting content into diagnostic products, and we are going to see the emergence of the new markets that we’ve talked about, agricultural markets emerging because of the price for data point now is so low and the emergence of the consumer markets. So, all in all I think it's a very bright opportunity in terms of both technology and the market place.
- To read the full transcript on Seeking Alpha, click here »
